None of the authors have had any relationships with a manufacturer of a β2-agonist or anticholinergic agent at any time.
Meta-analysis: Anticholinergics, but not β-agonists, Reduce Severe Exacerbations and Respiratory Mortality in COPD
Article first published online: 31 MAY 2006
Journal of General Internal Medicine
Volume 21, Issue 10, pages 1011–1019, October 2006
How to Cite
Salpeter, S. R., Buckley, N. S. and Salpeter, E. E. (2006), Meta-analysis: Anticholinergics, but not β-agonists, Reduce Severe Exacerbations and Respiratory Mortality in COPD. Journal of General Internal Medicine, 21: 1011–1019. doi: 10.1111/j.1525-1497.2006.00507.x
- Issue published online: 4 SEP 2006
- Article first published online: 31 MAY 2006
- Manuscript received December 23, 2005Initial editorial decision March 3, 2006Final acceptance April 4, 2006
- chronic obstructive pulmonary disease;
- adrenergic β-agonists;
- cholinergic antagonists;
- muscarinic antagonists;
- clinical outcomes;
BACKGROUND: Anticholinergics and β2-agonists have generally been considered equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD).
OBJECTIVE: To assess the safety and efficacy of anticholinergics and β2-agonists in COPD.
DESIGN: We comprehensively searched electronic databases from 1966 to December 2005, clinical trial websites, and references from selected reviews. We included randomized controlled trials of at least 3 months duration that evaluated anticholinergic or β2-agonist use compared with placebo or each other in patients with COPD.
MEASUREMENTS: We evaluated the relative risk (RR) of exacerbations requiring withdrawal from the trial, severe exacerbations requiring hospitalization, and deaths attributed to a lower respiratory event.
RESULTS: Pooled results from 22 trials with 15,276 participants found that anticholinergic use significantly reduced severe exacerbations (RR 0.67, confidence interval [CI] 0.53 to 0.86) and respiratory deaths (RR 0.27, CI 0.09 to 0.81) compared with placebo. β2-Agonist use did not affect severe exacerbations (RR 1.08, CI 0.61 to 1.95) but resulted in a significantly increased rate of respiratory deaths (RR 2.47, CI 1.12 to 5.45) compared with placebo. There was a 2-fold increased risk for severe exacerbations associated with β2-agonists compared with anticholinergics (RR 1.95, CI 1.39 to 2.93). The addition of β2-agonist to anticholinergic use did not improve any clinical outcomes.
CONCLUSION: Inhaled anticholinergics significantly reduced severe exacerbations and respiratory deaths in patients with COPD, while β2-agonists were associated with an increased risk for respiratory deaths. This suggests that anticholinergics should be the bronchodilator of choice in patients with COPD, and β2-agonists may be associated with worsening of disease control.